
In this explanatory monologue, the speaker compares three growth hormone‑releasing hormone (GHRH) mimetic peptides—Tesamorelin, Sermorelin, and CJC‑1295. Sermorelin and CJC‑1295 are described as fragment‑based analogues that are rapidly degraded by the enzyme dipeptidyl‑peptidase‑4 (DPP‑4). Their primary action is to stimulate the pituitary gland to release pulses of growth hormone. Tesamorelin, by contrast, is a full‑length 44‑amino‑acid clone of native GHRH, engineered for greater stability (approximately 40 minutes circulating). This longer half‑life lets Tesamorelin reach receptors outside the pituitary, notably on visceral fat tissue, where it can exert direct peripheral effects and produce tangible physical changes. The speaker uses vivid metaphors to emphasize Tesamorelin’s comprehensive, sustained activity versus the fleeting, “party‑crashing” nature of the fragment‑based peptides.











